EICHORPublic-registry trials using Rituximab that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.
| Trial | Sponsor | Condition | Phase | Sites |
| A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL | Loxo Oncology, Inc. | Chronic Lymphocytic Leukemia | PHASE1 / PHASE2 | 56 |
| First FDA approval | RITUXAN — November 1997 (application BLA103705, currently held by GENENTECH) |
| Approval timeline | RITUXAN 1997 (GENENTECH) → RITUXAN HYCELA 2017 (GENENTECH INC) → TRUXIMA 2018 (CELLTRION INC) → RUXIENCE 2019 (PFIZER INC) → RIABNI 2020 (AMGEN INC) |
| Also known as | RITUXAN · RITUXAN HYCELA · TRUXIMA · RUXIENCE · RIABNI |
| Approved applications | 5 — a multi-source (generic) drug |
| Forms & routes | Injectable, Solution · Injection, Intravenous, Subcutaneous |
| Registry-wide use | 2,790 registered studies all-time · 355 currently recruiting |
Sources: FDA Drugs@FDA and ClinicalTrials.gov, public records. The application holder shown is the current holder, which may differ from the original developer.
Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Trialed alongside
Other Chronic Lymphocytic Leukemia drugs
← Eichor home · All tracked trials · Chronic Lymphocytic Leukemia studies · Weekly briefs
